Quarterly report · Q2
7459.TEDINET S100S94Y
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.78T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥3.36T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.69T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥20.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥25.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥29.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥65.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥33.3bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥32.8bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥33.3bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥17.2bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥38.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥22.5bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥21.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥1.82T | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥1.71T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.74T | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.10T | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥1.02T | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥714.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥688.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥674.7bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥209.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥195.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥207.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥193.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥238.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥260.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥31.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥9.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥10.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥39.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥12.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥43.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥80.48 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.08 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥184.82 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.51 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥43.13 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥179.12 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.56 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 32.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥1.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥37m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥56.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥56.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥583.4bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥583.3bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥146m |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.14T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.14T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.78T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.78T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥20.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥191m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥36.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥36.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥554.9bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥554.7bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥174m |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.10T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.09T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.69T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.69T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥25.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 508
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYTDDuration | 5744000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 238524000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 206983000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1093897000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 554723000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 36775000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1685396000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 1685396000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1802000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 174000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1979000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -1979000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1095699000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 554898000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 36777000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1687375000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -1979000000 | JPY |
| Net sales | Prior1YTDDuration | 1685396000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 12017000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 11959000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1375000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 25352000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | 191000000 | JPY |
| Operating income | Prior1YTDDuration | 25543000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1138946000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 583273000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 56769000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1778989000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1778989000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1055000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 146000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1203000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -1203000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1140001000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 583420000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 56771000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1780193000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -1203000000 | JPY |
| Net sales | CurrentYTDDuration | 1778989000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 5362000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 13769000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1537000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 20668000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -37000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |